Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study.

HJ, Burstein; A, Keshaviah; AD, Baron; RD, Hart; R, Lambert-Falls; PK, Marcom; R, Gelman; EP, Winer

doi:10.1002/cncr.22885

Public

Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study.

Shared by NobleBlocks on Sep 1, 2007 • 12:00 AM UTC

Authors:

Burstein HJ

Keshaviah A

Baron AD

Abstract

<h4>Background</h4>The optimal trastuzumab-based chemotherapy regimen for HER2-overexpressing, metastatic breast cancer is not known. The trastuzumab and vinorelbine or taxane (TRAVIOTA) study was a prospective, multicenter, randomized trial that was designed to compare these regimens.<h4>Methods</h...

Discussions